Topical Combo based on Pfizer and Novartis Drugs advances after Clearing early Clinical test
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…
Synopsis: Pfizer’s JAK inhibitor Xeljanz and Novartis’ S1P modulator Gilenya both have their share of safety problems. But Vyne Therapeutics thinks it…
Summary : In just two short years, BioNTech will have more than doubled the size of its workforce at the German biologics…
Summary : CDMO giant Catalent completed expansion projects worth $10 million that added large-scale isolator units to its Malvern, Pennsylvania, and Dartford,…
Summary : On his company’s recent spending spree to build manufacturing capacity, Fujifilm Diosynth CEO Martin Meeson said three months ago: “We’re…
Summary : Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines. As interest…
Summary : The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed…
Summary : A team of scientists led by chief scientist Ravishankar is working on two combinations to provide the safest medication to coronavirus patients.…
Summary : Singapore will extend its COVID-19 booster vaccination programme to adolescents aged 12 to 17 years from next month, its health…
Chennai: The city-based laboratory says it has developed an RT-PCR test kit that can detect the Covid-19 virus in 45 minutes and…
Synopsis : Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies…